iSpecimen (ISPC) Q2 2026 earnings summary

Executive summary

• Revenue for the six months ended June 30, 2026, declined 83% year-over-year to $308,000, driven by a 75% drop in specimen count and lower average selling prices.

• Net loss for the six months was $3.6 million, a 34% increase from the prior year, despite significant cost reductions.

• The company implemented workforce reductions and operational streamlining, resulting in a 17% decrease in monthly compensation costs compared to the prior year period.

• Substantial doubt exists regarding the company's ability to continue as a going concern, with management's plans to mitigate this uncertainty not considered probable.

Financial highlights

• Revenue fell to $308,000 for the six months ended June 30, 2026, from $1.77 million in the prior year period.

• Net loss increased to $3.6 million from $2.7 million year-over-year.

• Cash and cash equivalents decreased to $4.4 million as of June 30, 2026, from $6.9 million at year-end 2025.

• Working capital deficit stood at $993,000 as of June 30, 2026.

• Sales and marketing expenses rose 245% to $2.1 million, primarily due to increased advertising and promotion.

Outlook and guidance

• Management is focused on revenue enhancement projects, cost containment, and capital raising, but acknowledges uncertainty in achieving these goals.

• The company plans to leverage operational improvements and a new account-based sales approach to drive future growth.